Quarterly report · Q1
2784.TEDINET S100OYAV
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥657.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥643.6bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥3.8bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥3.7bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.7bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.6bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.2bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥3.2bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥1.33T | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.34T | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥852.5bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥475.5bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥486.2bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥178.2bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥10.5 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.32 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.8% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.3% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥7.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥7.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥82m |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥585.4bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥580.9bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.0bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.9bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.1bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥207m |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥8.8bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥8.8bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥92m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥59.6bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥59.5bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥142m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥664.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥657.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥7.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥7.1bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | ¥126m |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥567.7bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥563.5bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥4.2bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥3.0bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥11.1bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥8.2bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥534m |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥8.4bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥8.4bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥272m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥63.6bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥63.5bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥113m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥444m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥650.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥643.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥7.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥3.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 376
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都千代田区大手町１丁目１－３ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income single statement (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding contingency liability (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |